Impact TB vaccination for PLHIV
Modelling to inform PPCs for TB VX for PLHIV
Modelling
TB case-finding in the context of future vaccines
Scenarios for future TB vaccines’ characteristics within which the value and cost-effectiveness of present-day interventions can be explored
Modelling the health and economic impacts of M72/AS01EÂ vaccination and BCG-revaccination: estimates for South Africa
we used a mathematical model to estimate the health impact and cost-effectiveness of M72/AS01E and BCG-revaccination in South Africa under a range of vaccine characteristics and delivery assumptions
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.
The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries
We assessed the potential financial risk protection from introducing novel TB vaccines, and how health and economic benefits would be distributed across income quintiles.
Conducting market analyses for new tuberculosis vaccines for adolescents and adults: A summary of one approach applied to M72/AS01E
A summary report of the methodology used in the MM Global Health Consulting (MMGH) market anlysis and the high-level findings and recommendations.
Acceptability and effect on public and cost-effectiveness impact
Understanding the acceptability of new TB vaccines, and their impact on health, cost-effectiveness, and budget, by socio-economic and risk group, in likely early adopter and other archetype countries.